QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S

Reuters

Sep 02

QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S

Qiagen NV has received U.S. FDA clearance for its QIAstat-Dx Rise, a high-throughput version of the QIAstat-Dx automated syndromic testing system. This approval enables the launch of QIAstat-Dx Rise in the U.S., which can process up to 160 samples per day. The system initially includes the Respiratory Panel Plus and Respiratory Panel Mini, with additional panels in development. This marks Qiagen's third FDA-cleared QIAstat-Dx product in 2025 and expands its portfolio of syndromic testing solutions, already available in over 100 countries. Plans are underway to introduce gastrointestinal panels to the system in the coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250901414875) on September 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564337873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564337873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564337873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564337873","market":"us","top_or_hot":-1,"title":"QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qiagen NV has received U.S. FDA clearance for its QIAstat-Dx Rise, a high-throughput version of the QIAstat-Dx automated syndromic testing system. This approval enables the launch of QIAstat-Dx Rise in the U.S., which can process up to 160 samples per day. The system initially includes the Respiratory Panel Plus and Respiratory Panel Mini, with additional panels in development. This marks Qiagen's third FDA-cleared QIAstat-Dx product in 2025 and expands its portfolio of syndromic testing solutions, already available in over 100 countries. Plans are underway to introduce gastrointestinal panels to the system in the coming months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250901414875) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qiagen NV has received U.S. FDA clearance for its QIAstat-Dx Rise, a high-throughput version of the QIAstat-Dx automated syndromic testing system. This approval enables the launch of QIAstat-Dx Rise in the U.S., which can process up to 160 samples per day. The system initially includes the Respiratory Panel Plus and Respiratory Panel Mini, with additional panels in development. This marks Qiagen's third FDA-cleared QIAstat-Dx product in 2025 and expands its portfolio of syndromic testing solutions, already available in over 100 countries. Plans are underway to introduce gastrointestinal panels to the system in the coming months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250901414875) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL5PTfmy:1","article_id":"2564337873","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564337873","pubTimestamp":1756791017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Qiagen NV has received U.S. FDA clearance for its QIAstat-Dx Rise, a high-throughput version of the QIAstat-Dx automated syndromic testing system. This approval enables the launch of QIAstat-Dx Rise in the U.S., which can process up to 160 samples per day. The system initially includes the Respiratory Panel Plus and Respiratory Panel Mini, with additional panels in development. This marks Qiagen's third FDA-cleared QIAstat-Dx product in 2025 and expands its portfolio of syndromic testing solutions, already available in over 100 countries. Plans are underway to introduce gastrointestinal panels to the system in the coming months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate thi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD"},"translate_title":"QIAGEN获得FDA高通量QIAstat-Dx Rise许可，增强了美国的综合征检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S\n    \n\n        Qiagen NV has received U.S. FDA clearance for its QIAstat-Dx Rise, a high-throughput version of the QIAstat-Dx automated syndromic testing system. This approval enables the launch of QIAstat-Dx Rise in the U.S., which can process up to 160 samples per day. The system initially includes the Respiratory Panel Plus and Respiratory Panel Mini, with additional panels in development. This marks Qiagen's third FDA-cleared QIAstat-Dx product in 2025 and expands its portfolio of syndromic testing solutions, already available in over 100 countries. Plans are underway to introduce gastrointestinal panels to the system in the coming months.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250901414875) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}